Cooper Companies buying Sauflon

Sauflon forecasts revenue of approximately $210 million for its fiscal year ending 31 October, up approximately 22% year-over-year.
The transaction is subject to regulatory approval and is expected to close prior to fiscal year end, 31 October 2014. Excluding one-time charges and deal-related amortisation, the transaction is expected to be accretive to earnings per share in fiscal 2015. The acquisition will be financed with off-shore cash and credit facilities.
Commenting on the transaction, Mr Robert Weiss, Cooper’s president and chief executive officer, said: “We are extrely pleased to announce this acquisition which gives CooperVision the world’s most comprehensive portfolio of daily-disposable lenses. CooperVision will now be able to offer a multi-tier daily strategy that includes a full suite of silicone hydrogel and hydrogel lenses, including options within all categories – spheres, torics and multifocals. The daily segment is the fastest growing segment of the soft-contact-lens market and this transaction positions CooperVision as the prier company in this space.”
The Cooper Companies is a global medical device company publicly traded on the New York Stock Exchange. It operates through two business units, CooperVision and CooperSurgical. CooperVision produces a wide range of high-quality products for contact-lens wearers. CooperSurgical focuses on supplying women’s health products and treatment.
Headquartered in Pleasanton, California, Cooper has approximately 8,000 ployees with products sold in over 100 countries.
Established in 1985, Sauflon is a privately-owned British company and a global manufacturer of contact lenses and after-care solutions. It has three state-of-the-art manufacturing plants, sales offices in 10 countries, and products sold in over 50 countries. Sauflon is recognized as a high-quality, award-winning global manufacturer of contact lenses and after-care products.